{
    "nctId": "NCT00935558",
    "briefTitle": "Dendritic Cell Based Therapy for Breast Cancer Patients",
    "officialTitle": "Evaluation of p53peptide-pulsed Dendritic Cells in Combination With an Aromatase Inhibitor as a Treatment for Patients With Breast Cancer With Disease Recurrence After Adjuvant or First Line Endocrine Therapy.",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "To determine time to progression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histological proven metastatic or locally advanced ER+/PGR+ breast cancer in progression after receiving 1. line endocrine therapy.\n* Further inclusion criteria: p53+ tumour, PS\u22641, postmenopausal. Age \\>18, PS \u2264 1 and acceptable CBC and blood chemistry results\n\nExclusion Criteria:\n\n* Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinoma in situ of the cervix and basal/squamous carcinoma of the skin)\n* Patients with metastatic disease in the central nervous system\n* Patients with other significant illness including severe allergy, asthma, DM, angina pectoris or congestive heart failure\n* Patients with acute or chronic infection including HIV, hepatitis og TB\n* Patients who received antineoplastic therapy including chemotherapy, radiation, immunotherapy or other agents, less than 4 weeks before the beginning of the trial\n* Patients who received corticosteroids or other immunosuppressive agents\n* Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis\n* Severe hypercalcemia",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}